Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Rating of “Hold” from Analysts

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have been given a consensus recommendation of “Hold” by the six brokerages that are presently covering the firm, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $52.50.

A number of brokerages recently weighed in on AGIO. Leerink Partners downgraded Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $60.00 to $56.00 in a research report on Friday, September 27th. StockNews.com lowered shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, August 5th. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Friday, September 20th. Leerink Partnrs cut Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 27th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $55.00 price objective on shares of Agios Pharmaceuticals in a report on Thursday, September 19th.

Insider Activity at Agios Pharmaceuticals

In other news, CFO Cecilia Jones sold 2,542 shares of the company’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $49.03, for a total value of $124,634.26. Following the sale, the chief financial officer now owns 20,158 shares in the company, valued at $988,346.74. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Brian Goff sold 11,091 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $42.75, for a total value of $474,140.25. Following the completion of the transaction, the chief executive officer now owns 78,792 shares in the company, valued at approximately $3,368,358. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Cecilia Jones sold 2,542 shares of the business’s stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $49.03, for a total value of $124,634.26. Following the completion of the sale, the chief financial officer now owns 20,158 shares of the company’s stock, valued at $988,346.74. The disclosure for this sale can be found here. 4.93% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Agios Pharmaceuticals

A number of hedge funds have recently made changes to their positions in AGIO. Acadian Asset Management LLC acquired a new stake in Agios Pharmaceuticals during the 2nd quarter worth $37,000. Quest Partners LLC purchased a new position in shares of Agios Pharmaceuticals in the second quarter worth about $40,000. North Star Asset Management Inc. acquired a new position in Agios Pharmaceuticals during the second quarter worth about $216,000. XTX Topco Ltd purchased a new stake in Agios Pharmaceuticals during the 2nd quarter valued at about $230,000. Finally, Northcape Wealth Management LLC acquired a new stake in Agios Pharmaceuticals in the 2nd quarter valued at about $244,000.

Agios Pharmaceuticals Trading Down 2.9 %

Shares of AGIO stock opened at $40.56 on Friday. Agios Pharmaceuticals has a twelve month low of $19.80 and a twelve month high of $53.28. The stock has a fifty day simple moving average of $45.34 and a two-hundred day simple moving average of $40.02. The stock has a market capitalization of $2.30 billion, a price-to-earnings ratio of -6.42 and a beta of 0.75.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). Agios Pharmaceuticals had a negative return on equity of 47.05% and a negative net margin of 1,165.69%. The business had revenue of $8.60 million during the quarter, compared to analysts’ expectations of $9.34 million. During the same period last year, the company earned ($1.51) earnings per share. The firm’s revenue was up 28.4% compared to the same quarter last year. Research analysts predict that Agios Pharmaceuticals will post -4.85 EPS for the current fiscal year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.